Detection of Unknown Primary Tumors Using Whole Body FDG PET

Zhao Jun,Lin Xiangtong,Guan Yihui,Zuo Chuantao,Hua Fengchun,Sheng Xiaofang,Wang Yang

DOI: https://doi.org/10.1007/bf02842297

2003-01-01

Abstract:Objective : To assess the usefulness of 2-[fluorine-18]fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET) in locating occult primary lesions. Methods : 50 patients with varying heterogeneous metastases of unknown primary origin were referred for FDG PET. The locations of the known metastatic tumor manifestations were distributed as follows: cervical lymph nodes metastases ( n =18), skeletal metastases ( n =15), cerebral metastases ( n =12), others ( n =5). All patients underwent whole body 18 F-FDG PET imaging. The images were interpreted by visual inspection and semi-quantitative analysis (standardized uptake value, SUV). The patients had undergone conventional imaging within 2 weeks of FDG PET. Surgical, clinical and histopathologic findings were used to assess the performance of FDG PET. Results : FDG PET was able to detect the location of the primary tumor in 32/50 patients (64%). The primary tumors were proved by histopathologic results, and located in the lungs ( n =17), the nasopharynx ( n =9), the breast ( n =2), the ovary ( n =1), the colon ( n =1), the prostate ( n =1), the thyroid ( n =1). FDG PET were proved false positive in 2 patients (4%), and the suspicious primary tumors were in uterus and colon respectively. During the clinical follow-up of 2 to 26 months, the primary tumor was found in only 2 patients (prostate cancer, gastric cancer). Conclusion : PET imaging allows identification of the primary site and metastatic lesions(including bone and soft tissue metastases) at a single examination. Whole body 18 F-FDG PET allows effective localization of the unknown primary site of origin and can contribute substantially to patient care.